FDA Oncology Announcements

ROS1 inhibitor × Clear all

3 Announcements

FDA approves taletrectinib for ROS1-positive non-small cell lung cancer

Trial: TRUST-II
Drug: Ibtrozi (taletrectinib) · ROS1 inhibitor
Condition: Thoracic

FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors

Trial: TRIDENT-1
Drug: AUGTYRO (repotrectinib) · ROS1 inhibitor
Condition: Other solid neoplasm

FDA approves repotrectinib for ROS1-positive non-small cell lung cancer

Drug: Augtyro (repotrectinib) · ROS1 inhibitor
Condition: Thoracic